Breaking News Instant updates and real-time market news.

ZLAB

Zai Lab

$25.70

0.17 (0.67%)

, TSRO

Tesaro

$0.00

(0.00%)

07:35
01/28/19
01/28
07:35
01/28/19
07:35

Zai Lab receives priority review status for Zejula NDA from NMPA

Zai Lab (ZLAB) announced that the Center for Drug Evaluation of China's National Medical Products Administration, or NMPA, has granted priority review status to the new drug application, or NDA, for Zejula for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal ovarian cancer who are in a complete or partial response to platinum-based chemotherapy. Zejula is a potent and highly selective PARP1/2 inhibitor that does not require BRCA mutation or other biomarker testing prior to administration. Zai Lab in-licensed rights to Zejula from Tesaro (TSARO) for China, Hong Kong and Macau as an important, new treatment option for more than 50,000 Chinese patients who suffer from ovarian cancer every year. Zejula is a potential best-in-class PARP inhibitor due to its differentiated efficacy, once-daily dosing and superior pharmacokinetic properties including its ability to cross the blood brain barrier. The NDA was accepted by the NMPA on December 12, 2018. Zai Lab obtained approval for marketing Zejula in Hong Kong in October 2018 and has been actively commercializing the product.

ZLAB

Zai Lab

$25.70

0.17 (0.67%)

TSRO

Tesaro

$0.00

(0.00%)

ZLAB Zai Lab
$25.70

0.17 (0.67%)

11/21/18
JEFF
11/21/18
INITIATION
Target $34
JEFF
Buy
Zai Lab initiated with a Buy at Jefferies
Jefferies analyst Maury Raycroft started Zai Lab with a Buy rating and $34 price target. The analyst likes the company's structure of forming partnerships around assets that are already clinically de-risked. The partnerships reduce risk and allow Zai Lab to accelerate a drug's path to market in China, Raycroft tells investors in a research note.
06/21/18
LEER
06/21/18
INITIATION
Target $43
LEER
Outperform
Zai Lab assumed with an Outperform at Leerink
Leerink analyst Jonathan Chang assumed coverage of Zai Lab with an Outperform rating and $43 price target as he believes it is well-positioned to execute.
02/14/18
JPMS
02/14/18
UPGRADE
Target $35
JPMS
Overweight
Zai Lab upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded Zai Lab to Overweight and raised his price target for the shares to $35 from $32. The analyst continues to view the company as an attractive healthcare emerging markets story in China, and now believes shares represent an attractive long-term entry point. The analyst adds that the FPA144 deal is an "underappreciated oncology tuck-in, with a meaningful target market opportunity."
TSRO Tesaro
$0.00

(0.00%)

12/14/18
LEER
12/14/18
NO CHANGE
LEER
Outperform
Tesaro proxy documents point to interest in PARP economics, says Leerink
Leerink analyst Andrew Berens noted that GlaxoSmithKline (GSK) and Tesaro (TSRO) disclosed background details for their deal agreement in a filing this morning. The documents show several parties were interested in a strategic transaction with Tesaro at various points over the last year, though the strategic interest appears to have been driven by Glaxo and one additional company, identified as "Party A", Berens said. It is not clear why the six other contacted parties were not interested in pursuing a strategic transaction, but he thinks Party A's co-promote proposal and the initial interest of other potential acquirers indicates strategic interest in the economics surrounding a PARP. Berens, who continues to see Clovis (CLVS) being well-positioned as the remaining stand-alone PARP-focused company, keeps an Outperform rating on Clovis and Market Perform rating on Tesaro.
12/11/18
GABE
12/11/18
NO CHANGE
GABE
Buy
Gabelli sees Clovis as likely takeout target, top biotech pick in 2019
Gabelli analyst Jing He highlights Clovis (CLVS) as his top biotech pick in 2019. With the Tesaro (TSRO) acquisition by GlaxoSmithKline (GSK), Clovis will become the only standalone PARP, which the analyst believes makes it the most likely takeout target in 2019. He continues to believe Bristol-Myers (BMY), Sanofi (SNY) and Roche (RHHBY) to be the most interested buyers. The analyst reiterates a Buy rating on Clovis' shares.
12/10/18
LEHM
12/10/18
DOWNGRADE
Target $75
LEHM
Equal Weight
Tesaro downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Gena Wang downgraded Tesaro (TSRO) to Equal Weight citing the takeover by GlaxoSmithKline (GSK). The analyst raised her price target for the shares to $75 from $48.
12/05/18
CANT
12/05/18
DOWNGRADE
Target $75
CANT
Neutral
Tesaro downgraded to Neutral from Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young downgraded Tesaro (TSRO) to Neutral to reflect the takeover by GlaxoSmithKline (GSK). The analyst raised her price target for the shares to $75 from $68.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.